ORPH

Orphazyme AS Share Price

7.24
1.27 (21.27%)
Upgrade to Real-Time
Afterhours (Closed)
7.24
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Orphazyme AS ORPH NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
1.27 21.27% 7.24 19:59:56
Open Price Low Price High Price Close Price Prev Close
6.10 6.09 9.35 7.44 5.97
Bid Price Ask Price Spread News
7.24 7.25 0.01 - 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
461,164 132,130,269  7.62  1,006,239,358 20,022,733 4.75 - 77.77
Last Trade Time Type Quantity Stock Price Currency
19:59:58 formt 100  7.24 USD

Orphazyme AS Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 253.05M 34.95M 34.95M  -  - -3.66 -1.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - - -

more financials information »

News Orphazyme AS

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

ORPH Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Orphazyme AS is a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins. It is engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for four severe orphan diseases: Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).


Your Recent History
NASDAQ
ORPH
Orphazyme ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.